<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03447886</url>
  </required_header>
  <id_info>
    <org_study_id>17-581</org_study_id>
    <secondary_id>U54CA156732</secondary_id>
    <nct_id>NCT03447886</nct_id>
  </id_info>
  <brief_title>Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds</brief_title>
  <official_title>Understanding Barriers to Initiation and Adherence to Adjuvant Endocrine Therapy in Young Breast Cancer Survivors of Diverse Racial, Ethnic, and Socio-economic Backgrounds: The EMPOWER Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to qualitatively explore how behavioral, cultural,
      psychosocial, and economic barriers and facilitators affect the decision to start and adhere
      to endocrine therapy (ET) among young breast cancer survivors of diverse racial, ethnic, and
      socio-economic backgrounds with hormone receptor positive (HR+) breast cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A qualitative study that will use interviews to gain an in depth understanding of factors
      affecting the decision to start and adhere to endocrine therapy (ET) among young breast
      cancer survivors of diverse racial, ethnic, and socio-economic backgrounds with hormone
      receptor positive (HR+) breast cancer
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Decision-making around endocrine therapy in young women with HR+ breast cancer.</measure>
    <time_frame>6 months-2 years post active treatment</time_frame>
    <description>Open ended questions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Barriers and challenges to endocrine therapy adherence</measure>
    <time_frame>6 months-2 years post active treatment</time_frame>
    <description>Open ended questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social support</measure>
    <time_frame>6 months-2 years post active treatment</time_frame>
    <description>Open ended questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health behaviors</measure>
    <time_frame>6 months-2 years post active treatment</time_frame>
    <description>Open ended questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine therapy adherence intervention preferences</measure>
    <time_frame>6 months-2 years post active treatment</time_frame>
    <description>Open ended questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health literacy</measure>
    <time_frame>6 months-2 years post active treatment</time_frame>
    <description>Brief Health Literacy Screener (Chew items)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menopausal symptoms</measure>
    <time_frame>6 months-2 years post active treatment</time_frame>
    <description>BCPT Symptom Checklist</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Quality Of Life</arm_group_label>
    <description>This study uses qualitative research methods, specifically semi-structured interviews.
This will include moderator guide development,
Phone interviews with breast cancer survivors will be conducted
Qualitative data analysis of the phone interviews will be conducted</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phone interview</intervention_name>
    <description>Collecting clinical and socio-demographic information.</description>
    <arm_group_label>Quality Of Life</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women of all races
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are Hispanic, Latina, Black, or identify as socio-economically disadvantaged (any
             racial/ethnic background) as measured by an item of financial distress answering that
             they are &quot;having difficulty paying the bills no matter what they do&quot; to a question
             about their current household financial situation.18, 19

          -  report a history of Stage 1-3 breast cancer

          -  reports HR+ breast cancer and confirm that they have had a discussion with their
             doctor about adjuvant ET; OR indicate that they are taking ET, even if they do not
             know their HR status, answer they are HR-, or do not recall having a discussion about
             ET)

          -  not in active treatment (e.g., chemotherapy, radiation), with the exception of
             Herceptin

          -  at least 6 months, but no more than 2 years out of completion of active treatment

          -  no evidence of recurrent/metastatic disease

          -  at least 18, but&lt; 45 years of age at diagnosis of first invasive breast cancer

          -  English or Spanish speaking

          -  are willing to consent to the interview

        Exclusion Criteria:

          -  HR- breast cancer and indicate they are not taking ET

          -  HR+ breast cancer but do not confirm discussion of ET or indicate they are taking ET

          -  Stage 0 (DCIS) breast cancer

          -  Recurrent or metastatic disease

          -  Less than 6 months or more than 2 years post-active treatment

          -  Less than 18 years old or â‰¥45 years old at diagnosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shoshana M. Rosenberg, ScD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shoshana m. Rosenberg, ScD, MPH</last_name>
    <phone>617-582-7593</phone>
    <email>Shoshana_Rosenberg@dfci.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shoshana M. Rosenberg, ScD, MPH</last_name>
      <phone>617-582-7593</phone>
      <email>Shoshana_Rosenberg@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Shoshana M. Rosenberg, ScD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2018</study_first_submitted>
  <study_first_submitted_qc>February 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Shoshana M. Rosenberg</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

